Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.

Trial Profile

Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Pixantrone (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EXTEND
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 17 Jun 2013 Results from post-hoc sub-set analyses presented at the 18th Congress of the European Hematology Association, according to a Cell Therapeutics media release.
    • 29 May 2012 Results published in Lancet Oncology.
    • 06 Dec 2010 Results will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top